Business Trip

This is part 2 or our 3 part series on microdosing that explore the science, history, and clinical applications. In part 1, we interviewed psychedelic researcher James Fadiman about the fundamentals of microdosing. In part 2, we wanted to understand the placebo effect. In particular, is it the microdose that makes people feel better or it is a placebo effect? We interviewed Balázs Szigeti PhD, who is a researcher associate at the Centre for Psychedelic Research at Imperial College London. His team conducted the largest placebo-controlled microdosing study in 2020. Balázs unpacks the study and their findings in the episode.Credits: Created by Greg Kubin and Matias SerebrinskyHost:  Greg Kubin and Matias SerebrinskyProduced by Jonathan A. Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack FrankZone Out by Daniel FridellLinks to topics discussed in this episode:Self-blinding citizen science to explore psychedelic microdosing (Szigeti et al., 2021)Centre for Psychedelic Research - Imperial College LondonStatistical and clinical significance

In this 3-part series on microdosing, we explore the science, history, and its clinical potential. The anecdotal benefits of microdosing include better mood, creativity, and increased focus. But there are still many unanswered questions that remain. What is an effective dosing protocol? Is it safe in long term use? Does it even work or is it a placebo effect?In part 1, we chat with James Fadiman, Ph.D who has been researching psychedelics since the 1960’s. He's the author of several books, including the Psychedelic Explorer's Guide. He has collected thousands of microdosing reports and even has his own microdosing protocol - called the Fadiman protocol. When we talk about standing on the shoulders of giants, James Fadiman is one of them.Credits: Created by Greg Kubin and Matias SerebrinskyHost:  Greg Kubin Produced by Jonathan A. Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack FrankLinks to topics discussed in this episode:Jim's microdosing websiteSofia UniversityThe Psychedelic Explorer's GuidePsychedelics Promote Structural and Functional Neural Plasticity (Ly et al, 2018)

In this week’s episode, we chat with Matt Zorn, an attorney at Yetter Coleman with expertise in DEA law, especially regarding psychedelics. Matt is currently challenging the DEA’s decision to schedule 5 new tryptamines, he recently argued Kathryn Tucker’s psilocybin “Right To Try” case against the DEA, and previously co-led Sue Sisley’s DEA case related to cannabis scheduling. Matt also writes the drug policy newsletter On Drugs.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

In this week’s special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. The episode was recorded in front of a live audience. Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research at the US Veterans Affairs Medical Center.  She is the Director at the Mental Health Patient Care Center at the James J. Peters VA Medical Center, Director of the Center for Psychedelic Psychotherapy and Trauma Research at Mount Sinai Hospital, as well as Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai Hospital. Zach Haigney writes the Trip Report by Beckley Waves, a newsletter about the science, policy, and business of psychedelics.Credits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

In Episode 18, we chat with Jonathan Sabbagh and Myriam Barthes, the co-founders of Journey Clinical, a platform that enables licensed therapists to offer ketamine-assisted psychotherapy (KAP). Journey Clinical provides licensed therapists with an on-demand KAP-trained medical team, customized treatments for each client, and a portal to connect with other therapists and educational resources.In this episode, we discuss:The journey from idea to 100+ therapist membersHow ketamine-assisted therapy works and the Journey Clinical's vision for the futureBalancing growth with protecting the relationship between patient and therapistCredits: Created by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

In today’s episode, we chat with Lucia Huang, the CEO and co-founder of Osmind, an electronic health record software system for treatment resistant mental health practices that is already in over 300 clinics. In this episode, we discuss:How Osmind makes data-driven decisions Osmind’s quick growth in only 2 yearsWhat it will take for insurance to cover ketamine therapy, as well as other psychedelic therapiesCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

In today’s episode, we chat with Tim Schlidt, a partner at Palo Santo. Palo Santo is a fund investing in psychedelic therapeutics. Palo Santo’s portfolio includes companies like Eleusis, Tactogen, and Journey Clinical.In this episode, we discuss:Tim’s background in healthcare financeInvesting in classic psychedelic compounds vs. 2nd generation compoundsHallmarks of a good first meeting with a prospective investmentCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional Music: Distant Daze by Zack Frank

Today’s episode features Dillan Dinardo and Tom Ray, the co-founders of Mindstate Design Labs. Mindstate has a unique framework to design psychedelic compounds using what they call the “primer probe method.” This method involves combining a known psychedelic with a non-psychedelic compound. Mindstate just raised an $11.5M seed round.In this episode, we discuss:Tom and Dillan’s experience in YCombinator and raising an $11.5M seed roundTom’s friendship with the late psychedelic chemist Alexander ShulginMindstate’s lead programsThe role of mystical states in the healing processCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian Love

Today’s episode features Amy Emerson, the CEO of MAPS Public Benefit Corporation (PBC), which is a fully owned subsidiary of MAPS, and its purpose is to commercialize MDMA-assisted therapy. We discuss the MAPS PBC and it’s business model for MDMA-assisted therapy.In this episode, we discuss:MAPS’ protocol and strategy behind FDA clinical trial for PTSDAmy’s views on the state of the industry, patents, and how to prioritize accessibilityThe unique business model between MAPS and MAPS PBCPsychedelics for kidsCreated by Greg Kubin and Matias SerebrinskyHost: Greg Kubin and Matias SerebrinskyProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghFind us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: Focus Does the Girl by Muted Circus

In today’s episode, we discuss what it’s like being a psychologist who owns a psychedelic clinic. Genesee Herzberg is the co-founder of Sage Integrative Health, an integrative clinic in Berkeley, CA that offers ketamine-assisted therapy (KAP), psychotherapy, somatic therapy, and acupuncture. Genesee discusses her holistic approach to healing, and shares her experience bootstrapping her clinic and setting up a non-profit to make KAP more affordable.In this episode, we discuss:Ketamine-assisted psychotherapy and the difference between high and low dose ketamine treatmentsWhat it takes to get a for-profit clinic off the ground while running a non-profit organizationSage Institute’s mission to make ketamine-assisted psychotherapy affordable for everyoneGenesee’s long term goals for the future of psychedelic medicineCreated by Greg Kubin and Matias SerebrinskyHost: Matias Serebrinsky & Greg KubinProduced by Jonathan A. Davis & Zack FrankMarketing by DaisyMae VanValkenburghRead the transcript here.Find us at businesstrip.fmFollow us on Instagram and Twitter!Theme music by Dorian LoveAdditional music: Flocean by Zack Frank